Clinical Trials Browser

Phase 2 × Withdrawn × dostarlimab × Clear all

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

GastrointestinalOther solid neoplasm

MMR-D/MSI-H Colorectal Cancers

NCT05405192 2023-02-28

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Phase 2 Withdrawn

Gestational Trophoblastic Disease

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma